Advertisement

Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis

  • John D. Isaacs
    Correspondence
    Address correspondence to: Prof. John D. Isaacs, Institute of Cellular Medicine, Faculty of Medical Sciences, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.
    Affiliations
    Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

    Musculoskeletal Unit, Newcastle Upon Tyne Hospitals National Health Service (NHS) Foundation Trust, Newcastle Upon Tyne, United Kingdom
    Search for articles by this author
  • Kundan Iqbal
    Affiliations
    Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

    Musculoskeletal Unit, Newcastle Upon Tyne Hospitals National Health Service (NHS) Foundation Trust, Newcastle Upon Tyne, United Kingdom
    Search for articles by this author

      Abstract

      Rheumatoid arthritis (RA) immunopathology starts many years before clinical disease manifests. An early event is the breakdown in B-cell tolerance and the emergence of autoantibodies. Some years later, the autoantibody response matures, with epitope spreading and isotype switching suggesting more focused T-cell involvement. Circulating proinflammatory cytokines and chemokines appear concurrently, marking a phase of preclinical inflammation. Eventually individuals develop musculoskeletal symptoms and fatigue, heralding the imminent onset of synovitis. The prevention of RA can be aligned to these disease stages, which may simplistically be viewed as breach of tolerance, maturation of autoimmunity, and subclinical inflammation. At each stage, an "ethical" balance must be struck between the potential for benefit versus harm, in large part determined by the likelihood of progression to RA. In particular, tolerogenic interventions should be favored during asymptomatic disease, providing long-lasting, possibly lifelong, benefit from a short-term intervention. During the breach-of-tolerance phase, tolerogenic interventions might involve the administration of autoantigenic peptides in an attempt to shut down autoreactive B cells. The peptides may be "naked," encapsulated in nanoparticles or loaded into autologous tolerogenic dendritic cells. It may also be possible to interfere with antigen generation and presentation, such as via peptidyl arginine deiminase inhibition. Attempts to interfere with B cells via depletion, differentiation, or intracellular signaling are also logical at this stage, if deemed sufficiently well tolerated. These interventions remain relevant during maturation of autoimmunity, but targeted T-cell interventions also become relevant, such as co-stimulation blockade and, potentially, interventions that target intracellular signaling pathways within T cells. Targeting of interleukin 23 during this phase may interfere with maturation of the autoantibody response by modulating autoantibody glycosylation, as well as by inhibiting T-helper 17 differentiation. During the phase of subclinical inflammation, targeting cytokines and chemokines could conceivably prevent progression to RA. Furthermore, tolerance induction is opposed by systemic inflammation and, during this phase, it may be necessary to consider therapeutic combinations of tolerogenic and antiinflammatory interventions.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gerlag D.M.
        • Raza K.
        • van Baarsen L.G.
        • et al.
        EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis.
        Ann Rheum Dis. 2012; 71: 638-641
        • Deane K.D.
        • Holers V.M.
        Natural history of rheumatoid arthritis.
        Clin Ther. 2019; 41: 1256-1267
        • van Steenbergen H.W.
        • Aletaha D.
        • Beaart-van de Voorde L.J.
        • et al.
        EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.
        Ann Rheum Dis. 2017; 76: 491-496
        • Zaccardelli A.
        • Friedlander H.
        • Ford J.
        • Sparks J.
        Potential of lifestyle changes for reducing the risk of developing rheumatoid arthritis: is an ounce of prevention worth a pound of cure?.
        Clin Ther. 2019; 41: 1323-1345
        • Demoruelle K.
        Mucosal biology and the development of rheumatoid arthritis: potential for prevention by targeting mucosal processes.
        Clin Ther. 2019; 41: 1270-1278
        • Isaacs J.D.
        The changing face of rheumatoid arthritis: sustained remission for all?.
        Nat Rev. 2010; 10: 605-611
        • Baka Z.
        • Gyorgy B.
        • Geher P.
        • Buzas E.I.
        • Falus A.
        • Nagy G.
        Citrullination under physiological and pathological conditions.
        Joint Bone Spine. 2012; 79: 431-436
        • Suzuki A.
        • Kochi Y.
        • Shoda H.
        • et al.
        Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice.
        BMC Musculoskelet Disord. 2016; 17: 205
        • Willis V.C.
        • Banda N.K.
        • Cordova K.N.
        • et al.
        Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis.
        Clin Exp Immunol. 2017; 188: 263-274
        • Kawalkowska J.
        • Quirke A.M.
        • Ghari F.
        • et al.
        Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses.
        Sci Rep. 2016; 6: 26430
        • Trouw L.A.
        • Rispens T.
        • Toes R.E.M.
        Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.
        Nat Rev Rheumatol. 2017; 13: 331-339
        • Cully M.
        Bristol-Myers Squibb acquires potential keys to treating rheumatoid arthritis.
        Nat Rev Drug Disc. 2016; 15: 301
        • Alhadj Ali M.
        • Liu Y.F.
        • Arif S.
        • et al.
        Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes.
        Sci Transl Med. 2017; 9eaaf7779
        • Chataway J.
        • Martin K.
        • Barrell K.
        • et al.
        Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
        Neurology. 2018; 90: e955-e962
        • Bielekova B.
        • Goodwin B.
        • Richert N.
        • et al.
        Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
        Nat Med. 2000; 6: 1167-1175
        • Clemente-Casares X.
        • Blanco J.
        • Ambalavanan P.
        • et al.
        Expanding antigen-specific regulatory networks to treat autoimmunity.
        Nature. 2016; 530: 434-440
        • Maldonado R.A.
        • LaMothe R.A.
        • Ferrari J.D.
        • et al.
        Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.
        Proc Natl Acad Sci U S A. 2015; 112: E156-E165
        • Getts D.R.
        • Martin A.J.
        • McCarthy D.P.
        • et al.
        Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.
        Nat Biotechnol. 2012; 30: 1217-1224
        • Carambia A.
        • Freund B.
        • Schwinge D.
        • et al.
        Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice.
        J Hepatol. 2015; 62: 1349-1356
        • Benham H.
        • Nel H.J.
        • Law S.C.
        • et al.
        Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients.
        Sci Transl Med. 2015; 7: 290ra87
        • Bell G.M.
        • Anderson A.E.
        • Diboll J.
        • et al.
        Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.
        Ann Rheum Dis. 2017; 76: 227-234
        • Giannoukakis N.
        • Phillips B.
        • Finegold D.
        • Harnaha J.
        • Trucco M.
        Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients.
        Diabetes Care. 2011; 34: 2026-2032
        • Jauregui-Amezaga A.
        • Cabezon R.
        • Ramirez-Morros A.
        • et al.
        Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn's disease: a phase I study.
        J Crohns Colitis. 2015; 9: 1071-1078
        • Mosanya C.H.
        • Isaacs J.D.
        Tolerising cellular therapies: what is their promise for autoimmune disease?.
        Ann Rheum Dis. 2019; 78: 297-310
        • Marek-Trzonkowska N.
        • Mysliwiec M.
        • Dobyszuk A.
        • et al.
        Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children.
        Diabetes Care. 2012; 35: 1817-1820
        • Bluestone J.A.
        • Buckner J.H.
        • Fitch M.
        • et al.
        Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
        Sci Transl Med. 2015; 7: 315ra189
        • Dall'Era M.
        • Pauli M.L.
        • Remedios K.
        • et al.
        Adoptive regulatory T cell therapy in a patient with systemic lupus erythematosus.
        Arthritis Rheumatol. 2019; 71: 431-440
        • Desreumaux P.
        • Foussat A.
        • Allez M.
        • et al.
        Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease.
        Gastroenterology. 2012; 143: 1207-12017 e2
        • Yeh W.I.
        • Seay H.R.
        • Newby B.
        • et al.
        Avidity and bystander suppressive capacity of human regulatory T cells expressing de novo autoreactive t-cell receptors in type 1 diabetes.
        Front Immunol. 2017; 8: 1313
        • Bluestone J.A.
        • Tang Q.
        Treg cells-the next frontier of cell therapy.
        Science. 2018; 362: 154-155
        • Canavan J.B.
        • Scotta C.
        • Vossenkamper A.
        • et al.
        Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.
        Gut. 2016; 65: 584-594
        • Baron U.
        • Floess S.
        • Wieczorek G.
        • et al.
        DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells.
        Eur J Immunol. 2007; 37: 2378-2389
        • Miyara M.
        • Gorochov G.
        • Ehrenstein M.
        • Musset L.
        • Sakaguchi S.
        • Amoura Z.
        Human FoxP3+ regulatory T cells in systemic autoimmune diseases.
        Autoimmun Rev. 2011; 10: 744-755
        • Saadoun D.
        • Rosenzwajg M.
        • Joly F.
        • et al.
        Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.
        N Engl J Med. 2011; 365: 2067-2077
        • Humrich J.Y.
        • von Spee-Mayer C.
        • Siegert E.
        • et al.
        Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.
        Ann Rheum Dis. 2015; 74: 791-792
        • Rosenzwajg M.
        • Lorenzon R.
        • Cacoub P.
        • et al.
        Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.
        Ann Rheum Dis. 2019; 78: 209-217
        • Todd J.A.
        • Evangelou M.
        • Cutler A.J.
        • et al.
        Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial.
        Plos Med. 2016; 13e1002139
        • Sokolove J.
        • Bromberg R.
        • Deane K.D.
        • et al.
        Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis.
        PLoS One. 2012; 7e35296
        • Derksen V.
        • Huizinga T.W.J.
        • van der Woude D.
        The role of autoantibodies in the pathophysiology of rheumatoid arthritis.
        Semin Immunopathol. 2017; 39: 437-446
        • Emery P.
        • Durez P.
        • Dougados M.
        • et al.
        Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).
        Ann Rheum Dis. 2010; 69: 510-516
        • Rayner F.
        • Isaacs J.D.
        Therapeutic tolerance in autoimmune disease.
        Semin Arthritis Rheum. 2018; 48: 558-562
        • Mjaavatten M.D.
        • Bykerk V.P.
        Early rheumatoid arthritis: the performance of the 2010 ACR/EULAR criteria for diagnosing RA.
        Best Pract Res. 2013; 27: 451-466
        • Keymeulen B.
        • Vandemeulebroucke E.
        • Ziegler A.
        • et al.
        Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
        N Engl J Med. 2005; 352: 2598-2608
        • Chamian F.
        • Lin S.L.
        • Lee E.
        • et al.
        Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
        J Transl Med. 2007; 5: 27
        • Baker K.F.
        • Isaacs J.D.
        Prospects for therapeutic tolerance in humans.
        Curr Opin Rheumatol. 2014; 26: 219-227
        • Schwartz D.M.
        • Bonelli M.
        • Gadina M.
        • O'Shea J.J.
        Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
        Nat Rev Rheumatol. 2016; 12: 25-36
        • Franks S.E.
        • Getahun A.
        • Hogarth P.M.
        • Cambier J.C.
        Targeting B cells in treatment of autoimmunity.
        Curr Opin Immunol. 2016; 43: 39-45
        • Gerlag D.M.
        • Safy M.
        • Maijer K.I.
        • et al.
        Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.
        Ann Rheum Dis. 2019; 78: 179-185
        • Ehrenstein M.
        • Evans J.
        • Singh A.
        • et al.
        Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy.
        J Exp Med. 2004; 200: 277-285
        • Kimura A.
        • Naka T.
        • Kishimoto T.
        IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells.
        Proc Natl Acad Sci U S A. 2007; 104: 12099-12104
        • Deane K.D.
        • O'Donnell C.I.
        • Hueber W.
        • et al.
        The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner.
        Arthritis Rheum. 2010; 62: 3161-3172
        • Kokkonen H.
        • Soderstrom I.
        • Rocklov J.
        • Hallmans G.
        • Lejon K.
        • Rantapaa Dahlqvist S.
        Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis.
        Arthritis Rheum. 2010; 62: 383-391
        • Burmester G.R.
        • McInnes I.B.
        • Kremer J.
        • et al.
        A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
        Ann Rheum Dis. 2017; 76: 1020-1030
        • Rombouts Y.
        • Willemze A.
        • van Beers J.J.
        • et al.
        Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis.
        Ann Rheum Dis. 2016; 75: 578-585
        • Pfeifle R.
        • Rothe T.
        • Ipseiz N.
        • et al.
        Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease.
        Nat Immunol. 2017; 18: 104-113
        • van Dongen H.
        • van Aken J.
        • Lard L.R.
        • et al.
        Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.
        Arthritis Rheum. 2007; 56: 1424-1432
        • Verstappen S.M.
        • McCoy M.J.
        • Roberts C.
        • et al.
        Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial.
        Ann Rheum Dis. 2010; 69: 503-509
        • Machold K.P.
        • Landewe R.
        • Smolen J.S.
        • et al.
        The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.
        Ann Rheum Dis. 2010; 69: 495-502
        • Burgers L.E.
        • Allaart C.F.
        • Huizinga T.W.J.
        • van der Helm-van Mil A.H.M.
        Brief report: clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: a trial of methotrexate versus placebo in undifferentiated arthritis as an example.
        Arthritis Rheumatol. 2017; 69: 926-931
        • Bos W.H.
        • Dijkmans B.A.
        • Boers M.
        • van de Stadt R.J.
        • van Schaardenburg D.
        Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial.
        Ann Rheum Dis. 2010; 69: 571-574
        • Brown P.M.
        • Pratt A.G.
        • Isaacs J.D.
        Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.
        Nat Rev Rheumatol. 2016; 12: 731-742
        • Regateiro F.S.
        • Cobbold S.P.
        • Waldmann H.
        CD73 and adenosine generation in the creation of regulatory microenvironments.
        Clin Exp Immunol. 2013; 171: 1-7
        • Joseph A.
        • Neff K.
        • Richard J.
        • et al.
        Transient low-dose methotrexate induces tolerance to murine anti-thymocyte globulin and together they promote long-term allograft survival.
        J Immunol. 2012; 189: 732-743
        • Karouzakis E.
        • Raza K.
        • Kolling C.
        • et al.
        Analysis of early changes in DNA methylation in synovial fibroblasts of RA patients before diagnosis.
        Sci Rep. 2018; 8: 7370
        • Firestein G.S.
        Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?.
        Arthritis Rheum. 1996; 39: 1781-1790
        • Klein K.
        • Kato M.
        • Frank-Bertoncelj M.
        • et al.
        Evaluating the bromodomain protein BRD1 as a therapeutic target in rheumatoid arthritis.
        Sci Rep. 2018; 8: 11125